Same precursor as for
Quifenadine. Note that the synthesis has changed over the years from the original. One route seems to involve a
Johnson–Corey–Chaykovsky reaction of the starting ketone, although another secondary route is also discussed.
References
^"Active substance: mequitazine"(PDF). List of nationally authorised medicinal products. Amsterdam: European Medicines Agency. 15 October 2020.
^Guminski Y, Fabre V, Lesimple P, Imbert T (June 1999). "An efficient synthesis of mequitazine". Organic Preparations and Procedures International. 31 (3): 319–323.
doi:
10.1080/00304949909458326.
^Leroux S, Larquetoux L, Nicolas M, Doris E (July 2011). "Asymmetric synthesis of (+)-mequitazine from quinine". Organic Letters. 13 (13): 3549–51.
doi:
10.1021/ol2012567.
PMID21657243.
Further reading
Ramírez Chanona N, del Rio Navarro BE, Pérez Martín J (November–December 2005). "[Efficacy of mequitazine (Primalan) on the relief of symptoms of allergic rhinoconjunctivitis in children. Documented clinical experience]". Revista Alergia Mexico (in Spanish). 52 (6): 221–225.
PMID16568706.
Theunissen EL, Vermeeren A, van Oers AC, van Maris I, Ramaekers JG (February 2004). "A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo". Clinical and Experimental Allergy. 34 (2): 250–258.
doi:
10.1111/j.1365-2222.2004.01874.x.
PMID14987305.
S2CID23019669.
Persi L, Dupin O, Arnaud B, Trinquand C, Michel FB, Bousquet J (April 1997). "Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis". Allergy. 52 (4): 451–454.
doi:
10.1111/j.1398-9995.1997.tb01028.x.
PMID9188930.
S2CID34785561.
External links
"Mequitazine". Drug Information Portal. U.S. National Library of Medicine.
Same precursor as for
Quifenadine. Note that the synthesis has changed over the years from the original. One route seems to involve a
Johnson–Corey–Chaykovsky reaction of the starting ketone, although another secondary route is also discussed.
References
^"Active substance: mequitazine"(PDF). List of nationally authorised medicinal products. Amsterdam: European Medicines Agency. 15 October 2020.
^Guminski Y, Fabre V, Lesimple P, Imbert T (June 1999). "An efficient synthesis of mequitazine". Organic Preparations and Procedures International. 31 (3): 319–323.
doi:
10.1080/00304949909458326.
^Leroux S, Larquetoux L, Nicolas M, Doris E (July 2011). "Asymmetric synthesis of (+)-mequitazine from quinine". Organic Letters. 13 (13): 3549–51.
doi:
10.1021/ol2012567.
PMID21657243.
Further reading
Ramírez Chanona N, del Rio Navarro BE, Pérez Martín J (November–December 2005). "[Efficacy of mequitazine (Primalan) on the relief of symptoms of allergic rhinoconjunctivitis in children. Documented clinical experience]". Revista Alergia Mexico (in Spanish). 52 (6): 221–225.
PMID16568706.
Theunissen EL, Vermeeren A, van Oers AC, van Maris I, Ramaekers JG (February 2004). "A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo". Clinical and Experimental Allergy. 34 (2): 250–258.
doi:
10.1111/j.1365-2222.2004.01874.x.
PMID14987305.
S2CID23019669.
Persi L, Dupin O, Arnaud B, Trinquand C, Michel FB, Bousquet J (April 1997). "Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis". Allergy. 52 (4): 451–454.
doi:
10.1111/j.1398-9995.1997.tb01028.x.
PMID9188930.
S2CID34785561.
External links
"Mequitazine". Drug Information Portal. U.S. National Library of Medicine.